Assessment of the anti-HBs antibody response in Beninese infants following 4 doses of HBV vaccine, including administration at birth, compared to the standard 3 doses regime; a cross-sectional survey
Hepatitis B virus (HBV) infection remains one of the major neglected health issues worldwide. In sub-Saharan Africa (SSA), HBV endemicity is high, with more than 8% of the population being chronic HBV carriers. Recently, WHO recommended that all infants should receive their first dose of the HBV vac...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2020-02, Vol.38 (7), p.1787-1793 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1793 |
|---|---|
| container_issue | 7 |
| container_start_page | 1787 |
| container_title | Vaccine |
| container_volume | 38 |
| creator | Accrombessi, Manfred Adetola, Crepin Victor Bacharou, Salwane Dossou, Yannelle Avokpaho, Euripide Yakoubou, Annatou Koumakpai-Adeothy, Sikiratou Lozes, Evelyne Issifou, Saadou |
| description | Hepatitis B virus (HBV) infection remains one of the major neglected health issues worldwide. In sub-Saharan Africa (SSA), HBV endemicity is high, with more than 8% of the population being chronic HBV carriers. Recently, WHO recommended that all infants should receive their first dose of the HBV vaccine as soon as possible after birth. Unfortunately, the incorporation of a birth dose of HBV in the expanded programme immunization (EPI) has not occurred in the majority of countries in SSA. From April to September 2017, a cross-sectional survey was conducted in two vaccine units located in southern Benin. We assessed the sustained anti-HBs antibody response in infants induced by a standard scheme of 3 doses of HBV vaccination (6, 10, 14 weeks) in comparison to a scheme of 4 doses with a birth dose included (0, 6, 10, 14 weeks). Blood samples were systematically collected in the first 140 children aged 9 months and their mothers who had consented to participate for the detection of HBs antigen and the quantification of anti-HBs antibodies. The prevalence of HBV infection among infants and mothers was 2.2% and 7.1%, respectively. Infants who received 4 doses of HBV vaccine had a significantly higher level of anti-HBs antibody than those who received 3 doses of vaccine (557.9 UI/L vs. 386.9 UI/L, respectively, P = 0.03). We also showed that the scheme of 4 doses was associated with a significantly higher sustained protective response in comparison to the scheme of 3 doses (aOR 2.49, 95% CI 1.03–6.03, P = 0.04). This result provides further evidence of the importance of administering HBV vaccine at birth, but also highlights the importance for the prevention of vertical transmissions. Additional studies are needed to better establish the cost-effectiveness of such a 4 doses immunization strategy before implementing the HBV vaccination at birth in the EPI. |
| doi_str_mv | 10.1016/j.vaccine.2019.12.031 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2330061885</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X19316731</els_id><sourcerecordid>2330061885</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-23db0c8f185f775ab26ca960e577e43fe1acb4d87a30fe7789f8161f3db1385a3</originalsourceid><addsrcrecordid>eNqFkc-O0zAQxiMEYsvCI4AsceGwCXacfxWH1XYFFGklLoC4WY493nWV2MXjFPUJeS2cNnDggmTJc_jNNzPfl2UvGS0YZc3bXXGQSlkHRUnZumBlQTl7lK1Y1_K8rFn3OFvRsqnyitHvF9kzxB2ltOZs_TS74KxrGtbVq-zXDSIgjuAi8YbEByDSRZtvN3gqeq-PJADuvUMg1pENuDT0VJsEIDF-GPxP6-5JRbRPYrPOdvONLPtdJVINk54JqUfrLMYgo_WOyEh6G-LDFVF-3MsAmkR_2gGjdFoGTfiiGeDejvCOSKKCR8wR1CwhB4JTOMDxefbEyAHhxfJfZl8_vP9yu83vPn_8dHtzl6uqojEvue6p6ky63bRtLfuyUXLdUKjbFipugEnVV7prJacG2rZbm441zKQ2xrta8svszVl3H_yPCTCK0aKCYZAO_ISi5JzSZG1XJ_T1P-jOTyGtPFN1SedXJao-U6e7AhixD3aU4SgYFXPSYicWJ8WctGClSEmnvleL-tSPoP92_Yk2AddnAJIdBwtBoLLgFGgbknlCe_ufEb8BThi_jw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2352052054</pqid></control><display><type>article</type><title>Assessment of the anti-HBs antibody response in Beninese infants following 4 doses of HBV vaccine, including administration at birth, compared to the standard 3 doses regime; a cross-sectional survey</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Accrombessi, Manfred ; Adetola, Crepin Victor ; Bacharou, Salwane ; Dossou, Yannelle ; Avokpaho, Euripide ; Yakoubou, Annatou ; Koumakpai-Adeothy, Sikiratou ; Lozes, Evelyne ; Issifou, Saadou</creator><creatorcontrib>Accrombessi, Manfred ; Adetola, Crepin Victor ; Bacharou, Salwane ; Dossou, Yannelle ; Avokpaho, Euripide ; Yakoubou, Annatou ; Koumakpai-Adeothy, Sikiratou ; Lozes, Evelyne ; Issifou, Saadou</creatorcontrib><description>Hepatitis B virus (HBV) infection remains one of the major neglected health issues worldwide. In sub-Saharan Africa (SSA), HBV endemicity is high, with more than 8% of the population being chronic HBV carriers. Recently, WHO recommended that all infants should receive their first dose of the HBV vaccine as soon as possible after birth. Unfortunately, the incorporation of a birth dose of HBV in the expanded programme immunization (EPI) has not occurred in the majority of countries in SSA. From April to September 2017, a cross-sectional survey was conducted in two vaccine units located in southern Benin. We assessed the sustained anti-HBs antibody response in infants induced by a standard scheme of 3 doses of HBV vaccination (6, 10, 14 weeks) in comparison to a scheme of 4 doses with a birth dose included (0, 6, 10, 14 weeks). Blood samples were systematically collected in the first 140 children aged 9 months and their mothers who had consented to participate for the detection of HBs antigen and the quantification of anti-HBs antibodies. The prevalence of HBV infection among infants and mothers was 2.2% and 7.1%, respectively. Infants who received 4 doses of HBV vaccine had a significantly higher level of anti-HBs antibody than those who received 3 doses of vaccine (557.9 UI/L vs. 386.9 UI/L, respectively, P = 0.03). We also showed that the scheme of 4 doses was associated with a significantly higher sustained protective response in comparison to the scheme of 3 doses (aOR 2.49, 95% CI 1.03–6.03, P = 0.04). This result provides further evidence of the importance of administering HBV vaccine at birth, but also highlights the importance for the prevention of vertical transmissions. Additional studies are needed to better establish the cost-effectiveness of such a 4 doses immunization strategy before implementing the HBV vaccination at birth in the EPI.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2019.12.031</identifier><identifier>PMID: 31866185</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Antibodies ; Antibody Formation ; Antibody response ; Antigens ; Babies ; Benin ; Benin - epidemiology ; Birth ; Consent ; Cross-Sectional Studies ; Enzymes ; Female ; Health facilities ; Hepatitis ; Hepatitis B ; Hepatitis B - prevention & control ; Hepatitis B Antibodies - immunology ; Hepatitis B Surface Antigens ; Hepatitis B Vaccines - immunology ; Hepatitis B virus ; Humans ; Immunization ; Immunization Schedule ; Infant ; Infant, Newborn ; Infants ; Infections ; Influenza ; Measles ; Parents & parenting ; Poliomyelitis ; Polls & surveys ; Population ; Sustained protective response ; Tetanus ; Vaccination ; Vaccination scheme ; Vaccines ; Viral infections ; Viruses ; Whooping cough ; Womens health</subject><ispartof>Vaccine, 2020-02, Vol.38 (7), p.1787-1793</ispartof><rights>2019 Elsevier Ltd</rights><rights>Copyright © 2019 Elsevier Ltd. All rights reserved.</rights><rights>2019. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-23db0c8f185f775ab26ca960e577e43fe1acb4d87a30fe7789f8161f3db1385a3</citedby><cites>FETCH-LOGICAL-c440t-23db0c8f185f775ab26ca960e577e43fe1acb4d87a30fe7789f8161f3db1385a3</cites><orcidid>0000-0001-9550-9413</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2352052054?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31866185$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Accrombessi, Manfred</creatorcontrib><creatorcontrib>Adetola, Crepin Victor</creatorcontrib><creatorcontrib>Bacharou, Salwane</creatorcontrib><creatorcontrib>Dossou, Yannelle</creatorcontrib><creatorcontrib>Avokpaho, Euripide</creatorcontrib><creatorcontrib>Yakoubou, Annatou</creatorcontrib><creatorcontrib>Koumakpai-Adeothy, Sikiratou</creatorcontrib><creatorcontrib>Lozes, Evelyne</creatorcontrib><creatorcontrib>Issifou, Saadou</creatorcontrib><title>Assessment of the anti-HBs antibody response in Beninese infants following 4 doses of HBV vaccine, including administration at birth, compared to the standard 3 doses regime; a cross-sectional survey</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Hepatitis B virus (HBV) infection remains one of the major neglected health issues worldwide. In sub-Saharan Africa (SSA), HBV endemicity is high, with more than 8% of the population being chronic HBV carriers. Recently, WHO recommended that all infants should receive their first dose of the HBV vaccine as soon as possible after birth. Unfortunately, the incorporation of a birth dose of HBV in the expanded programme immunization (EPI) has not occurred in the majority of countries in SSA. From April to September 2017, a cross-sectional survey was conducted in two vaccine units located in southern Benin. We assessed the sustained anti-HBs antibody response in infants induced by a standard scheme of 3 doses of HBV vaccination (6, 10, 14 weeks) in comparison to a scheme of 4 doses with a birth dose included (0, 6, 10, 14 weeks). Blood samples were systematically collected in the first 140 children aged 9 months and their mothers who had consented to participate for the detection of HBs antigen and the quantification of anti-HBs antibodies. The prevalence of HBV infection among infants and mothers was 2.2% and 7.1%, respectively. Infants who received 4 doses of HBV vaccine had a significantly higher level of anti-HBs antibody than those who received 3 doses of vaccine (557.9 UI/L vs. 386.9 UI/L, respectively, P = 0.03). We also showed that the scheme of 4 doses was associated with a significantly higher sustained protective response in comparison to the scheme of 3 doses (aOR 2.49, 95% CI 1.03–6.03, P = 0.04). This result provides further evidence of the importance of administering HBV vaccine at birth, but also highlights the importance for the prevention of vertical transmissions. Additional studies are needed to better establish the cost-effectiveness of such a 4 doses immunization strategy before implementing the HBV vaccination at birth in the EPI.</description><subject>Age</subject><subject>Antibodies</subject><subject>Antibody Formation</subject><subject>Antibody response</subject><subject>Antigens</subject><subject>Babies</subject><subject>Benin</subject><subject>Benin - epidemiology</subject><subject>Birth</subject><subject>Consent</subject><subject>Cross-Sectional Studies</subject><subject>Enzymes</subject><subject>Female</subject><subject>Health facilities</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B - prevention & control</subject><subject>Hepatitis B Antibodies - immunology</subject><subject>Hepatitis B Surface Antigens</subject><subject>Hepatitis B Vaccines - immunology</subject><subject>Hepatitis B virus</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Schedule</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Infants</subject><subject>Infections</subject><subject>Influenza</subject><subject>Measles</subject><subject>Parents & parenting</subject><subject>Poliomyelitis</subject><subject>Polls & surveys</subject><subject>Population</subject><subject>Sustained protective response</subject><subject>Tetanus</subject><subject>Vaccination</subject><subject>Vaccination scheme</subject><subject>Vaccines</subject><subject>Viral infections</subject><subject>Viruses</subject><subject>Whooping cough</subject><subject>Womens health</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc-O0zAQxiMEYsvCI4AsceGwCXacfxWH1XYFFGklLoC4WY493nWV2MXjFPUJeS2cNnDggmTJc_jNNzPfl2UvGS0YZc3bXXGQSlkHRUnZumBlQTl7lK1Y1_K8rFn3OFvRsqnyitHvF9kzxB2ltOZs_TS74KxrGtbVq-zXDSIgjuAi8YbEByDSRZtvN3gqeq-PJADuvUMg1pENuDT0VJsEIDF-GPxP6-5JRbRPYrPOdvONLPtdJVINk54JqUfrLMYgo_WOyEh6G-LDFVF-3MsAmkR_2gGjdFoGTfiiGeDejvCOSKKCR8wR1CwhB4JTOMDxefbEyAHhxfJfZl8_vP9yu83vPn_8dHtzl6uqojEvue6p6ky63bRtLfuyUXLdUKjbFipugEnVV7prJacG2rZbm441zKQ2xrta8svszVl3H_yPCTCK0aKCYZAO_ISi5JzSZG1XJ_T1P-jOTyGtPFN1SedXJao-U6e7AhixD3aU4SgYFXPSYicWJ8WctGClSEmnvleL-tSPoP92_Yk2AddnAJIdBwtBoLLgFGgbknlCe_ufEb8BThi_jw</recordid><startdate>20200211</startdate><enddate>20200211</enddate><creator>Accrombessi, Manfred</creator><creator>Adetola, Crepin Victor</creator><creator>Bacharou, Salwane</creator><creator>Dossou, Yannelle</creator><creator>Avokpaho, Euripide</creator><creator>Yakoubou, Annatou</creator><creator>Koumakpai-Adeothy, Sikiratou</creator><creator>Lozes, Evelyne</creator><creator>Issifou, Saadou</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9550-9413</orcidid></search><sort><creationdate>20200211</creationdate><title>Assessment of the anti-HBs antibody response in Beninese infants following 4 doses of HBV vaccine, including administration at birth, compared to the standard 3 doses regime; a cross-sectional survey</title><author>Accrombessi, Manfred ; Adetola, Crepin Victor ; Bacharou, Salwane ; Dossou, Yannelle ; Avokpaho, Euripide ; Yakoubou, Annatou ; Koumakpai-Adeothy, Sikiratou ; Lozes, Evelyne ; Issifou, Saadou</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-23db0c8f185f775ab26ca960e577e43fe1acb4d87a30fe7789f8161f3db1385a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age</topic><topic>Antibodies</topic><topic>Antibody Formation</topic><topic>Antibody response</topic><topic>Antigens</topic><topic>Babies</topic><topic>Benin</topic><topic>Benin - epidemiology</topic><topic>Birth</topic><topic>Consent</topic><topic>Cross-Sectional Studies</topic><topic>Enzymes</topic><topic>Female</topic><topic>Health facilities</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B - prevention & control</topic><topic>Hepatitis B Antibodies - immunology</topic><topic>Hepatitis B Surface Antigens</topic><topic>Hepatitis B Vaccines - immunology</topic><topic>Hepatitis B virus</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Schedule</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Infants</topic><topic>Infections</topic><topic>Influenza</topic><topic>Measles</topic><topic>Parents & parenting</topic><topic>Poliomyelitis</topic><topic>Polls & surveys</topic><topic>Population</topic><topic>Sustained protective response</topic><topic>Tetanus</topic><topic>Vaccination</topic><topic>Vaccination scheme</topic><topic>Vaccines</topic><topic>Viral infections</topic><topic>Viruses</topic><topic>Whooping cough</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Accrombessi, Manfred</creatorcontrib><creatorcontrib>Adetola, Crepin Victor</creatorcontrib><creatorcontrib>Bacharou, Salwane</creatorcontrib><creatorcontrib>Dossou, Yannelle</creatorcontrib><creatorcontrib>Avokpaho, Euripide</creatorcontrib><creatorcontrib>Yakoubou, Annatou</creatorcontrib><creatorcontrib>Koumakpai-Adeothy, Sikiratou</creatorcontrib><creatorcontrib>Lozes, Evelyne</creatorcontrib><creatorcontrib>Issifou, Saadou</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Accrombessi, Manfred</au><au>Adetola, Crepin Victor</au><au>Bacharou, Salwane</au><au>Dossou, Yannelle</au><au>Avokpaho, Euripide</au><au>Yakoubou, Annatou</au><au>Koumakpai-Adeothy, Sikiratou</au><au>Lozes, Evelyne</au><au>Issifou, Saadou</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of the anti-HBs antibody response in Beninese infants following 4 doses of HBV vaccine, including administration at birth, compared to the standard 3 doses regime; a cross-sectional survey</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2020-02-11</date><risdate>2020</risdate><volume>38</volume><issue>7</issue><spage>1787</spage><epage>1793</epage><pages>1787-1793</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Hepatitis B virus (HBV) infection remains one of the major neglected health issues worldwide. In sub-Saharan Africa (SSA), HBV endemicity is high, with more than 8% of the population being chronic HBV carriers. Recently, WHO recommended that all infants should receive their first dose of the HBV vaccine as soon as possible after birth. Unfortunately, the incorporation of a birth dose of HBV in the expanded programme immunization (EPI) has not occurred in the majority of countries in SSA. From April to September 2017, a cross-sectional survey was conducted in two vaccine units located in southern Benin. We assessed the sustained anti-HBs antibody response in infants induced by a standard scheme of 3 doses of HBV vaccination (6, 10, 14 weeks) in comparison to a scheme of 4 doses with a birth dose included (0, 6, 10, 14 weeks). Blood samples were systematically collected in the first 140 children aged 9 months and their mothers who had consented to participate for the detection of HBs antigen and the quantification of anti-HBs antibodies. The prevalence of HBV infection among infants and mothers was 2.2% and 7.1%, respectively. Infants who received 4 doses of HBV vaccine had a significantly higher level of anti-HBs antibody than those who received 3 doses of vaccine (557.9 UI/L vs. 386.9 UI/L, respectively, P = 0.03). We also showed that the scheme of 4 doses was associated with a significantly higher sustained protective response in comparison to the scheme of 3 doses (aOR 2.49, 95% CI 1.03–6.03, P = 0.04). This result provides further evidence of the importance of administering HBV vaccine at birth, but also highlights the importance for the prevention of vertical transmissions. Additional studies are needed to better establish the cost-effectiveness of such a 4 doses immunization strategy before implementing the HBV vaccination at birth in the EPI.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>31866185</pmid><doi>10.1016/j.vaccine.2019.12.031</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-9550-9413</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2020-02, Vol.38 (7), p.1787-1793 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2330061885 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Age Antibodies Antibody Formation Antibody response Antigens Babies Benin Benin - epidemiology Birth Consent Cross-Sectional Studies Enzymes Female Health facilities Hepatitis Hepatitis B Hepatitis B - prevention & control Hepatitis B Antibodies - immunology Hepatitis B Surface Antigens Hepatitis B Vaccines - immunology Hepatitis B virus Humans Immunization Immunization Schedule Infant Infant, Newborn Infants Infections Influenza Measles Parents & parenting Poliomyelitis Polls & surveys Population Sustained protective response Tetanus Vaccination Vaccination scheme Vaccines Viral infections Viruses Whooping cough Womens health |
| title | Assessment of the anti-HBs antibody response in Beninese infants following 4 doses of HBV vaccine, including administration at birth, compared to the standard 3 doses regime; a cross-sectional survey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T20%3A05%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20the%20anti-HBs%20antibody%20response%20in%20Beninese%20infants%20following%204%20doses%20of%20HBV%20vaccine,%20including%20administration%20at%20birth,%20compared%20to%20the%20standard%203%20doses%20regime;%20a%20cross-sectional%20survey&rft.jtitle=Vaccine&rft.au=Accrombessi,%20Manfred&rft.date=2020-02-11&rft.volume=38&rft.issue=7&rft.spage=1787&rft.epage=1793&rft.pages=1787-1793&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2019.12.031&rft_dat=%3Cproquest_cross%3E2330061885%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2352052054&rft_id=info:pmid/31866185&rft_els_id=S0264410X19316731&rfr_iscdi=true |